🍽️ flucytosine,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Antifungal Activity: Flucytosine works by inhibiting the synthesis of fungal DNA and RNA, interfering with the replication and proliferation of fungal cells. It is effective against certain species of Candida and Cryptococcus fungi, including some strains that may be resistant to other antifungal agents.

  2. Treatment of Cryptococcal Meningitis: Flucytosine is often used in combination with other antifungal medications, such as amphotericin B, for the treatment of cryptococcal meningitis, a serious fungal infection of the central nervous system caused by Cryptococcus neoformans. The combination therapy has been shown to improve outcomes in patients with this life-threatening infection.

  3. Treatment of Candidiasis: Flucytosine may also be used in the treatment of invasive candidiasis, a fungal infection caused by Candida species that can affect various organs and tissues in the body. It is sometimes used in combination with other antifungal agents, such as fluconazole or amphotericin B, for the treatment of severe or refractory cases of candidiasis.

  4. Dosage and Administration: Flucytosine is typically administered orally in the form of tablets or capsules. The dosage and duration of treatment depend on the specific type and severity of the fungal infection being treated, as well as the patient's overall health and response to therapy. Treatment regimens may involve high doses of flucytosine given multiple times per day.

  5. Side Effects: Common side effects of flucytosine may include gastrointestinal symptoms such as nausea, vomiting, diarrhea, and abdominal pain. These side effects are usually mild to moderate in severity and may improve with continued use of the medication. Rare but serious side effects may include bone marrow suppression (leading to leukopenia, thrombocytopenia, or anemia), liver toxicity, and renal impairment.

  6. Bone Marrow Suppression: Flucytosine can suppress the production of blood cells in the bone marrow, leading to a decrease in white blood cells, red blood cells, and platelets. Patients receiving flucytosine should undergo regular blood tests to monitor for signs of bone marrow suppression, and dosage adjustments may be necessary to prevent or manage hematologic toxicity.

  7. Hepatotoxicity: Flucytosine has the potential to cause liver damage, particularly in patients with pre-existing liver disease or impaired liver function. Liver function tests should be performed regularly during treatment with flucytosine, and the medication should be discontinued if significant liver abnormalities occur.

  8. Renal Toxicity: Flucytosine can accumulate in the kidneys and may cause renal toxicity, especially at higher doses or in patients with pre-existing renal impairment. Renal function should be monitored closely during treatment with flucytosine, and dosage adjustments may be necessary in patients with renal dysfunction.

  9. Contraindications and Precautions: Flucytosine is contraindicated in patients with known hypersensitivity to the drug or its components. It should be used with caution in patients with pre-existing bone marrow suppression, liver dysfunction, or renal impairment. Pregnant women should avoid flucytosine unless the potential benefits outweigh the risks, as its safety during pregnancy has not been established.

  10. Drug Interactions: Flucytosine may interact with other medications, particularly those that are renally excreted or that affect renal function. Concurrent use of nephrotoxic drugs or drugs that inhibit renal tubular secretion may increase the risk of renal toxicity when used with flucytosine.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations   |   βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of flucytosine,(prescription) On Probiotics

Rank Probiotic Impact
species Akkermansia muciniphila Reduces
species Bifidobacterium adolescentis Reduces
species Bifidobacterium longum Reduces
species Escherichia coli Reduces
species Lacticaseibacillus paracasei Reduces
subspecies Bifidobacterium longum subsp. infantis Reduces
subspecies Bifidobacterium longum subsp. longum Reduces

Bacteria Impacted by flucytosine,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Lacticaseibacillus genus Decreases 👪 Source Study
Blautia genus Decreases 👪 Source Study
Collinsella genus Decreases 👪 Source Study proinflammatory
Lacrimispora genus Decreases 👪 Source Study
Parabacteroides genus Decreases 👪 Source Study BMI, fat percent,blood pressure
Streptococcus genus Decreases 👪 Source Study
Veillonella genus Decreases 👪 Source Study
Coprococcus genus Decreases 👪 Source Study
Bifidobacterium genus Decreases 👪 Source Study
Bacteroides genus Decreases 👪 Source Study
Roseburia genus Decreases 👪 Source Study
Lachnospira genus Decreases 👪 Source Study
Clostridioides genus Decreases 👪 Source Study
Escherichia genus Decreases 👪 Source Study
Thomasclavelia genus Decreases 👪 Source Study
Odoribacter genus Decreases 👪 Source Study
Clostridium genus Decreases 👪 Source Study Pathogen
Ruminococcus genus Decreases 👪 Source Study
Dorea genus Decreases 👪 Source Study
Mediterraneibacter genus Decreases 👪 Source Study
Akkermansia genus Decreases 👪 Source Study
Fusobacterium genus Decreases 👪 Source Study Periodontal disease, Lemierre syndrome, skin ulcers
Eggerthella genus Decreases 👪 Source Study
Enterocloster genus Decreases 👪 Source Study
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
Escherichia coli O80:H26 no rank Decreases 👶 Source Study
Eggerthellales order Decreases ⚗️ Source Study
Escherichia coli O145 serogroup Decreases 👶 Source Study
Escherichia coli O157 serogroup Decreases 👶 Source Study
Escherichia coli O26 serogroup Decreases 👶 Source Study
Escherichia coli O43 serogroup Decreases 👶 Source Study
Escherichia coli O1:H42 serotype Decreases 👶 Source Study
Escherichia coli O104:H4 serotype Decreases 👶 Source Study
Escherichia coli O121:H19 serotype Decreases 👶 Source Study
Escherichia coli O127:H6 serotype Decreases 👶 Source Study
Escherichia coli O139:H28 serotype Decreases 👶 Source Study
Escherichia coli O157:H7 serotype Decreases 👶 Source Study bloody diarrhea
Escherichia coli O44:H18 serotype Decreases 👶 Source Study
Escherichia coli O55:H7 serotype Decreases 👶 Source Study
Escherichia coli O6:H16 serotype Decreases 👶 Source Study
Escherichia coli O7:K1 serotype Decreases 👶 Source Study
Lacticaseibacillus paracasei species Decreases 📓 Source Study
Blautia obeum species Decreases 📓 Source Study
Bacteroides caccae species Decreases 📓 Source Study
Collinsella aerofaciens species Decreases 📓 Source Study
Lacrimispora saccharolytica species Decreases 📓 Source Study
Streptococcus salivarius species Decreases 📓 Source Study Infectious bacteria
Parabacteroides distasonis species Decreases 📓 Source Study
Streptococcus parasanguinis species Decreases 📓 Source Study
Veillonella parvula species Decreases 📓 Source Study
Coprococcus comes species Decreases 📓 Source Study
Bifidobacterium adolescentis species Decreases 📓 Source Study
Bacteroides ovatus species Decreases 📓 Source Study
Bacteroides xylanisolvens species Decreases 📓 Source Study
Bifidobacterium longum species Decreases 📓 Source Study
Roseburia hominis species Decreases 📓 Source Study
Lachnospira eligens species Decreases 📓 Source Study
Clostridioides difficile species Decreases 📓 Source Study Colitis
Escherichia coli species Decreases 📓 Source Study Diarrheal disease in children and travelers, Foodborne diarrhea outbreaks, hemorrhagic colitis, hemolytic-uremic syndrome
Thomasclavelia ramosa species Decreases 📓 Source Study
Odoribacter splanchnicus species Decreases 📓 Source Study
[Ruminococcus] torques species Decreases 📓 Source Study
Clostridium perfringens species Decreases 📓 Source Study Food poisoning, gas gangrene
Ruminococcus bromii species Decreases 📓 Source Study
Bacteroides uniformis species Decreases 📓 Source Study Infectious bacteria
Bacteroides fragilis species Decreases 📓 Source Study H02076 Bacteroides infection
Dorea formicigenerans species Decreases 📓 Source Study
Akkermansia muciniphila species Decreases 📓 Source Study
Fusobacterium nucleatum species Decreases 📓 Source Study Infectious bacteria
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
Eggerthella lenta species Decreases 📓 Source Study
[Ruminococcus] gnavus species Decreases 📓 Source Study
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
Paraprevotella clara species Decreases ⚗️ Source Study
Slackia sp. NATTS species Decreases ⚗️ Source Study
Bacteroides thetaiotaomicron species Decreases 📓 Source Study
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
Enterocloster bolteae species Decreases 📓 Source Study
Coriobacterineae suborder Decreases ⚗️ Source Study
Lacticaseibacillus paracasei subsp. paracasei subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. infantis subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. longum subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. suillum subspecies Decreases 👶 Source Study
Fusobacterium nucleatum subsp. nucleatum subspecies Decreases 👶 Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of flucytosine,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Acne 0.3 -0.3
ADHD 3.3 0.4 7.25
Age-Related Macular Degeneration and Glaucoma 0.4 0.4 0
Allergic Rhinitis (Hay Fever) 1.1 1.4 -0.27
Allergies 3.8 1.3 1.92
Allergy to milk products 0.9 0.8 0.13
Alopecia (Hair Loss) 1.8 1.8
Alzheimer's disease 2.2 3.5 -0.59
Amyotrophic lateral sclerosis (ALS) Motor Neuron 2.1 0.7 2
Ankylosing spondylitis 3.4 0.9 2.78
Anorexia Nervosa 0.4 1.5 -2.75
Antiphospholipid syndrome (APS) 0.9 0.9
Asthma 0.6 0.8 -0.33
Atherosclerosis 1 0.8 0.25
Atrial fibrillation 2.9 1.1 1.64
Autism 5.4 5.6 -0.04
Barrett esophagus cancer 0.5 0.4 0.25
benign prostatic hyperplasia 0.2 0.2
Bipolar Disorder 0.9 1.2 -0.33
Brain Trauma 0.8 0.5 0.6
Carcinoma 3 2.3 0.3
Celiac Disease 1.5 3 -1
Cerebral Palsy 1.3 1.1 0.18
Chronic Fatigue Syndrome 3.5 4.7 -0.34
Chronic Kidney Disease 1.4 1.2 0.17
Chronic Lyme 0.5 -0.5
Chronic Obstructive Pulmonary Disease (COPD) 2.3 0.8 1.87
Chronic Urticaria (Hives) 1.4 0.5 1.8
Coagulation / Micro clot triggering bacteria 1.3 1.2 0.08
Colorectal Cancer 3.4 0.8 3.25
Constipation 0.6 0.7 -0.17
Coronary artery disease 0.8 1.2 -0.5
COVID-19 8.4 9.1 -0.08
Crohn's Disease 5.2 4 0.3
cystic fibrosis 0.6 0.7 -0.17
deep vein thrombosis 0.6 0.8 -0.33
Depression 8.7 7.1 0.23
Dermatomyositis 0.4 0.3 0.33
Eczema 0.7 1.9 -1.71
Endometriosis 2.8 0.9 2.11
Eosinophilic Esophagitis 0.1 0.3 -2
Epilepsy 2.5 1.7 0.47
Fibromyalgia 1.7 1.6 0.06
Functional constipation / chronic idiopathic constipation 3.3 2.8 0.18
gallstone disease (gsd) 1.8 0.6 2
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 0.7 1.3 -0.86
Generalized anxiety disorder 1.3 1.5 -0.15
giant cell arteritis 0.2 -0.2
Glioblastoma 0.4 -0.4
Gout 0.3 -0.3
Graves' disease 1.4 1.3 0.08
Halitosis 0.7 0.4 0.75
Hashimoto's thyroiditis 1.8 0.5 2.6
Hidradenitis Suppurativa 0.5 0.3 0.67
Histamine Issues,Mast Cell Issue, DAO Insufficiency 2.2 0.6 2.67
hypercholesterolemia (High Cholesterol) 0.3 0.2 0.5
hyperglycemia 0.2 1.7 -7.5
Hyperlipidemia (High Blood Fats) 0.9 0.5 0.8
hypersomnia 0.5 -0.5
hypertension (High Blood Pressure 2.2 3.8 -0.73
Hypothyroidism 1.2 -1.2
Hypoxia 0.7 0.7
IgA nephropathy (IgAN) 2 -2
Inflammatory Bowel Disease 3.6 5.2 -0.44
Insomnia 1.1 0.7 0.57
Intelligence 0.8 0.8
Intracranial aneurysms 1.2 0.5 1.4
Irritable Bowel Syndrome 3.3 2.7 0.22
Liver Cirrhosis 3.7 2.4 0.54
Long COVID 5.8 7 -0.21
Low bone mineral density 0.8 -0.8
Lung Cancer 1.1 1 0.1
ME/CFS with IBS 0.6 2.4 -3
ME/CFS without IBS 1.1 1.7 -0.55
Menopause 1.7 1.7
Metabolic Syndrome 6.6 5.6 0.18
Mood Disorders 10.9 7.2 0.51
multiple chemical sensitivity [MCS] 1.7 0.5 2.4
Multiple Sclerosis 4.5 3.3 0.36
Multiple system atrophy (MSA) 1.5 0.9 0.67
Neuropathy (all types) 1 0.2 4
neuropsychiatric disorders (PANDAS, PANS) 0.5 0.5
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 1.8 4.2 -1.33
NonCeliac Gluten Sensitivity 0.3 -0.3
Obesity 7 4.9 0.43
obsessive-compulsive disorder 4.9 2.4 1.04
Osteoarthritis 1.5 0.1 14
Osteoporosis 1.2 0.9 0.33
pancreatic cancer 0.5 0.5
Parkinson's Disease 2.7 2.7 0
Polycystic ovary syndrome 1.6 1.2 0.33
Postural orthostatic tachycardia syndrome 0.2 0.6 -2
Premenstrual dysphoric disorder 1.2 0.4 2
primary biliary cholangitis 0.1 0.7 -6
Psoriasis 3.8 2.2 0.73
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 5 2.7 0.85
Rosacea 0.8 0.4 1
Schizophrenia 5.1 1.6 2.19
scoliosis 0.3 0.6 -1
Sjögren syndrome 2.6 2.4 0.08
Sleep Apnea 1.4 1.4 0
Small Intestinal Bacterial Overgrowth (SIBO) 0.9 0.5 0.8
Stress / posttraumatic stress disorder 2 2 0
Systemic Lupus Erythematosus 3.1 1.5 1.07
Tic Disorder 0.3 0.9 -2
Tourette syndrome 0.1 0.2 -1
Type 1 Diabetes 2.6 1.6 0.63
Type 2 Diabetes 6.4 4.4 0.45
Ulcerative colitis 2.7 3 -0.11
Unhealthy Ageing 2.9 1.1 1.64

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.

Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.